A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Clarithromycin

Macrolide Antimicrobial class · 10 generic manufacturers · 18 ANDAs filed at FDA.

First FDA approval2005-08-25
Generic availableYes · 10 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$7.9M in CY2024 Part D spend280K claims · 240K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.393/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.457
Across all dosage forms in distribution.
Highest NADAC
$0.510
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Clarithromycin used for?

Clarithromycin is a Macrolide Antimicrobial medication tracked in Medicare Part D.

Is there a generic for Clarithromycin?

Yes. 18 ANDAs filed at FDA, 10 generic manufacturers currently shipping.

How much does my plan pay for Clarithromycin?

Across 329 Part D plans, Clarithromycin averages $0.457/unit (NADAC). Lowest available: $0.393/unit. Highest in distribution: $0.510/unit.

Is Clarithromycin on the FDA shortage list?

No. Clarithromycin is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.